TCW Group Inc. lessened its holdings in GlaxoSmithKline plc (NYSE:GSK) by 6.8% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 69,701 shares of the pharmaceutical company’s stock after selling 5,080 shares during the period. TCW Group Inc.’s holdings in GlaxoSmithKline were worth $2,473,000 as of its most recent SEC filing.
A number of other hedge funds have also modified their holdings of GSK. Field & Main Bank purchased a new stake in GlaxoSmithKline in the 4th quarter worth $132,000. First Dallas Securities Inc. purchased a new stake in GlaxoSmithKline in the 4th quarter worth $142,000. Wealthcare Advisory Partners LLC increased its stake in GlaxoSmithKline by 1,982.8% in the 3rd quarter. Wealthcare Advisory Partners LLC now owns 3,520 shares of the pharmaceutical company’s stock worth $143,000 after buying an additional 3,351 shares in the last quarter. Advisory Services Network LLC grew its position in shares of GlaxoSmithKline by 24.2% during the second quarter. Advisory Services Network LLC now owns 4,047 shares of the pharmaceutical company’s stock valued at $175,000 after purchasing an additional 788 shares in the last quarter. Finally, Waldron LP purchased a new position in shares of GlaxoSmithKline during the third quarter valued at about $203,000. Institutional investors and hedge funds own 9.17% of the company’s stock.
GlaxoSmithKline plc (GSK) opened at $36.65 on Thursday. The company has a debt-to-equity ratio of 4.09, a current ratio of 0.60 and a quick ratio of 0.39. GlaxoSmithKline plc has a 1-year low of $34.52 and a 1-year high of $44.53. The company has a market cap of $91,910.00, a PE ratio of 30.29, a P/E/G ratio of 2.34 and a beta of 0.98.
GlaxoSmithKline (NYSE:GSK) last announced its quarterly earnings results on Wednesday, February 7th. The pharmaceutical company reported $0.72 EPS for the quarter, beating the Zacks’ consensus estimate of $0.69 by $0.03. GlaxoSmithKline had a net margin of 4.97% and a return on equity of 130.63%. The firm had revenue of $10.14 billion during the quarter, compared to the consensus estimate of $9.89 billion. research analysts expect that GlaxoSmithKline plc will post 2.85 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, April 12th. Investors of record on Friday, February 23rd will be issued a $0.633 dividend. This is an increase from GlaxoSmithKline’s previous quarterly dividend of $0.50. The ex-dividend date is Thursday, February 22nd. This represents a $2.53 dividend on an annualized basis and a dividend yield of 6.91%. GlaxoSmithKline’s dividend payout ratio (DPR) is presently 168.60%.
A number of research analysts have recently weighed in on the company. Zacks Investment Research lowered GlaxoSmithKline from a “hold” rating to a “sell” rating in a research report on Wednesday. Cowen restated a “hold” rating and set a $40.00 price objective on shares of GlaxoSmithKline in a research report on Thursday, February 15th. Kepler Capital Markets upgraded GlaxoSmithKline from a “reduce” rating to a “hold” rating in a research report on Friday, February 9th. TheStreet lowered GlaxoSmithKline from a “b-” rating to a “c” rating in a research report on Wednesday, February 7th. Finally, JPMorgan Chase & Co. restated a “neutral” rating on shares of GlaxoSmithKline in a research report on Monday, February 5th. Three analysts have rated the stock with a sell rating, nine have issued a hold rating and five have given a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $38.97.
WARNING: This news story was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/22/tcw-group-inc-has-2-47-million-holdings-in-glaxosmithkline-plc-gsk.html.
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.